– Morgan Stanley Conf.
Related Posts
RBC Capital Upgrades Cerence to Sector Perform, Lowers Price Target to $27
RBC Capital analyst Joseph Spak upgrades Cerence (NASDAQ:CRNC) from Underperform to Sector Perform and lowers the price target from $28 to $27.
Gamida Cell Reports Preliminary Data From Phase 1 Study Of Natural Killer Cell Therapy Candidate GDA-201
Data show promising early evidence of anti-tumor activity in patients with relapsed/refractory B cell non-Hodgkin lymphomaFull data readout of Phase 1 study expected in Q1 2024Gamida Cell Ltd. (NASDAQ:GMDA), a cell
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Gainers
Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks.